Skip to contentL
Lifecore Biomedical, Inc.
L
LFCRLifecore Biomedical, Inc. Q1 2023 · 10-Q
Revenue$43.36M$43.36M+4.1% vs Q1 2022 Net Income-$11.35M-$11.35MN/M vs Q1 2022 EPS Diluted-$0.38-$0.38N/M vs Q1 2022 Gross Profit$6,252,000−40.1% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lifecore Biomedical, Inc. · CIK 1005286 · Engraved from SEC EDGAR
Operating Cash Flow-$1,533,000N/M Free Cash Flowderived-$4,462,000N/M Margins · derivedGross margin14.4%−10.6 pt vs Q1 2022
Operating margin-17.3%−10.7 pt vs Q1 2022
Net margin-26.2%−3.4 pt vs Q1 2022
ended Aug 28, 2022 · filed Oct 7, 2022 · 40 d after period end